GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Revenue

Sinopharm Group Co (Sinopharm Group Co) Revenue : $40,773 Mil (TTM As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Revenue?

Sinopharm Group Co's revenue for the three months ended in Sep. 2023 was $19,865 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $40,773 Mil. Sinopharm Group Co's Revenue per Share for the three months ended in Sep. 2023 was $6.41. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $13.11.

Good Sign:

Sinopharm Group Co Ltd has shown predictable revenue and earnings growth.

During the past 3 years, the average Revenue per Share Growth Rate was 7.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 11.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Sinopharm Group Co's highest 3-Year average Revenue per Share Growth Rate was 33.20% per year. The lowest was 7.40% per year. And the median was 15.45% per year.


Sinopharm Group Co Revenue Historical Data

The historical data trend for Sinopharm Group Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Revenue Chart

Sinopharm Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60,634.58 69,795.64 81,806.67 79,198.41 83,550.82

Sinopharm Group Co Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20,643.91 20,908.23 - 19,864.55 -

Competitive Comparison of Sinopharm Group Co's Revenue

For the Medical Distribution subindustry, Sinopharm Group Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's Revenue Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Revenue distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Revenue falls into.



Sinopharm Group Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $40,773 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sinopharm Group Co Revenue Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co (Sinopharm Group Co) Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Sinopharm Group was founded in 2003 and listed on the Hong Kong Stock Exchange in September 2009. Its main business is drug distribution in mainland China, which contributes about 75% of total revenue. It is the largest drug distributor, with approximately 20% market share. Other notable segments are medical device distribution, which contributes about 20% of revenue, and retail pharmacies, which contributes about 5%. These are fast-growing industries, where government policy is designed to encourage consolidation and promote large players with scale and efficiency advantages.

Sinopharm Group Co (Sinopharm Group Co) Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021